Clinical

Dataset Information

0

Dendritic Killer Cell-based Immunotherapy for Solid Tumors


ABSTRACT: The primary objective of this study is to evaluate the safety of autologous dendritic killer cell (DKC) in patients with metastatic solid tumor and to evaluate the maximum tolerated dose (MTD) of DKC. The primary endpoint of safety evaluation includes physical examination, assessment of vital sign, laboratory test, concomitant medication, and adverse event (AE). The secondary endpoints regarding efficacy includes the generation of tumor specific immune response by detecting CD3+ CD8+ CD69+ IFN-gamma+ T cells, and the improvement of quality of life

DISEASE(S): Neoplasm Metastasis,Colorectal Neoplasms,Neoplasms,Hepatocellular Carcinoma

PROVIDER: 2223614 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

2014-06-01 | E-GEOD-47621 | biostudies-arrayexpress
2014-06-01 | GSE47621 | GEO
2010-07-23 | E-GEOD-21889 | biostudies-arrayexpress
2010-07-23 | GSE21889 | GEO
2005-12-09 | GSE3337 | GEO
2007-09-11 | E-GEOD-3337 | biostudies-arrayexpress
2010-07-23 | E-GEOD-17301 | biostudies-arrayexpress
2024-02-15 | GSE247376 | GEO
2012-10-17 | E-GEOD-39556 | biostudies-arrayexpress
2011-06-22 | E-GEOD-29949 | biostudies-arrayexpress